×

Fibrocell Science Announces Chief Financial Officer Transition

EXTON, Pa., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced the Company's Board of Directors has appointed Kimberly M. Smith, the Company's Controller, to serve as Interim Chief Financial Officer, Treasurer and Corporate Secretary, effective immediately. Ms. Smith is replacing Gregory Weaver who served as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of Fibrocell Science since August 2013.

"We would like to thank Greg for his contributions at Fibrocell Science," said David Pernock, Chairman and CEO of Fibrocell.

Ms. Smith will continue to serve as the Controller of the Company, a position she has held since January 2014. Prior to joining Fibrocell, Ms. Smith was a financial consultant with AC Lordi from 2010 to 2013 working exclusively for AC Lordi's client, ViroPharma. Ms. Smith began her career with Ernst & Young in 1998. Ms. Smith is a Certified Public Accountant and also holds the Chartered Global Management Accountant designation.

"Kimberly has a strong background in accounting and finance, and we are confident that she is well-suited for these additional responsibilities," said Christine St.Clare, Audit Committee Chairman.

Fibrocell will initiate an executive search to identify the permanent Chief Financial Officer.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The Company's collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products. For additional information, visit www.fibrocellscience.com.

CONTACT: Investor Relations: Susan Noonan S.A. Noonan Communications, LLC (212) 966-3650 susan@sanoonan.comSource:Fibrocell Science, Inc.